Display options
Cite
De Nayer A, De Hert M, Scheen A, et al. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Psychiatry Clin Pract. 2005;9(2):130-7doi: 10.1080/13651500510018310.
De Nayer, A., De Hert, M., Scheen, A., Van Gaal, L., Peuskens, J., On Behalf Of The Consensus Group, De Nayer, A., De Hert, M., Scheen, A., Van Gaal, L., Peuskens, J., & On Behalf Of The Consensus Group. (2005). Belgian consensus on metabolic problems associated with atypical antipsychotics. International journal of psychiatry in clinical practice, 9(2), 130-7. https://doi.org/10.1080/13651500510018310
De Nayer, A, et al. "Belgian consensus on metabolic problems associated with atypical antipsychotics." International journal of psychiatry in clinical practice vol. 9,2 (2005): 130-7. doi: https://doi.org/10.1080/13651500510018310
De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J, On Behalf Of The Consensus Group, De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J, On Behalf Of The Consensus Group. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Psychiatry Clin Pract. 2005;9(2):130-7. doi: 10.1080/13651500510018310. PMID: 24930795.
Copy Download .nbib Format: NLM
Share it on

Int J Psychiatry Clin Pract. 2005;9(2):130-7. doi: 10.1080/13651500510018310.

Belgian consensus on metabolic problems associated with atypical antipsychotics.

International journal of psychiatry in clinical practice

A De Nayer, M De Hert, A Scheen, L Van Gaal, J Peuskens, On Behalf Of The Consensus Group, A De Nayer, M De Hert, A Scheen, L Van Gaal, J Peuskens, On Behalf Of The Consensus Group

Affiliations

  1. Hôpital Sainte-Thérèse, Montignie sur Sambre, Belgium.

PMID: 24930795 DOI: 10.1080/13651500510018310

Abstract

A workshop was convened by a panel of psychiatrists, diabetologists and pharmacists from major Belgian hospitals to review the latest information relating to the risks with second-generation antipsychotics (SGA) for the development of metabolic disorders, especially impaired glucose tolerance, diabetes mellitus and dyslipidemia. The panelists sought to formulate recommendations for practising psychiatrists when initiating and maintaining therapy with SGA, and for the switch of SGA or initiation of further treatment if metabolic complications occur. In addition, recommendations for counselling of the patient and for the cooperation between the psychiatrist and the general physician or diabetologist, respectively, were provided.

Keywords: Consensus; diabetes; dyslipidemia; metabolic; second-generation antipsychotics

Publication Types